Abstract
This article provides information about modern representation of non-alcoholic fatty liver disease, as well as the structure, role and function of vascular endothelium in the pathogenesis of steatosis. The article presents the results of remaxol in clinical practice in patients with nonalcoholic fatty liver disease. Investigated hepatic and endothelial protective effects of remaxol 5–10 day treatment and 30 days after of therapy. Early clinical effect was expressed in the normalization of endothelial function, which is the first marker of positive action endothelial protective effects of remaxol, compared with laboratory and sonographic evidence.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
